Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

184

Enrollment

NIH

Sponsor class

Conditions

Metastatic Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Bladder Urothelial Carcinoma
Refractory Urothelial Carcinoma
Stage IV Bladder Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Scan
PROCEDURE: Computed Tomography
DRUG: Docetaxel
DRUG: Eribulin Mesylate
DRUG: Gemcitabine Hydrochloride
PROCEDURE: Magnetic Resonance Imaging
DRUG: Paclitaxel
BIOLOGICAL: Sacituzumab Govitecan

Sponsor

National Cancer Institute (NCI)